247 related articles for article (PubMed ID: 37355297)
1. [Classical nephroprotection: Renin angiotensin aldosterone system inhibitors].
Egocheaga MI; Drak Y; Otero V
Semergen; 2023 Jun; 49 Suppl 1():102018. PubMed ID: 37355297
[TBL] [Abstract][Full Text] [Related]
2. Renin-angiotensin-aldosterone system blockers effect in chronic kidney disease progression in hypertensive elderly patients without proteinuria: PROERCAN trial.
García-Prieto AM; Verdalles Ú; de José AP; Arroyo D; Aragoncillo I; Barbieri D; Camacho RE; Goicoechea M
Hipertens Riesgo Vasc; 2024; 41(2):95-103. PubMed ID: 38508877
[TBL] [Abstract][Full Text] [Related]
3. Can patiromer allow for intensified renin-angiotensin-aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: MorphCKD.
Mårup FH; Peters CD; Christensen JH; Birn H
BMJ Open; 2022 Feb; 12(2):e057503. PubMed ID: 35190442
[TBL] [Abstract][Full Text] [Related]
4. Mineralcorticoid receptor blockers in chronic kidney disease.
Erraez S; López-Mesa M; Gómez-Fernández P
Nefrologia (Engl Ed); 2021; 41(3):258-275. PubMed ID: 36166243
[TBL] [Abstract][Full Text] [Related]
5. The renin-angiotensin-aldosterone system blockade in patients with advanced diabetic kidney disease.
Bermejo S; García CO; Rodríguez E; Barrios C; Otero S; Mojal S; Pascual J; Soler MJ
Nefrologia (Engl Ed); 2018; 38(2):197-206. PubMed ID: 29102270
[TBL] [Abstract][Full Text] [Related]
6. Use of renin-angiotensin-aldosterone system blockade in controversial chronic kidney disease populations.
García-Prieto AM; Verdalles Ú; Goicoechea M
Med Clin (Barc); 2021 Jun; 156(11):561-567. PubMed ID: 33757646
[TBL] [Abstract][Full Text] [Related]
7. The effect of renin-angiotensin-aldosterone system blockers on the progression of chronic kidney disease in hypertensive elderly patients without proteinuria: PROERCAN study. Rationale and design.
García-Prieto AM; Verdalles Ú; de José AP; Verde E; Arroyo D; Aragoncillo I; Linares T; Barbieri D; Goicoechea M
Hipertens Riesgo Vasc; 2020; 37(3):101-107. PubMed ID: 32156479
[TBL] [Abstract][Full Text] [Related]
8. Detrimental effect of renin-angiotensin blockade on progression of chronic kidney disease at later stages: A matter of dosage adjustment?
Caravaca-Fontán F; Valladares J; Díaz-Campillejo R; Barroso S; Luna E; Caravaca F
Nefrologia (Engl Ed); 2020; 40(1):38-45. PubMed ID: 31196659
[TBL] [Abstract][Full Text] [Related]
9. The Use of Renin-Angiotensin System Inhibitors in Patients With Chronic Kidney Disease.
Leon SJ; Tangri N
Can J Cardiol; 2019 Sep; 35(9):1220-1227. PubMed ID: 31472818
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic approaches in lowering albuminuria: travels along the renin-angiotensin-aldosterone-system pathway.
Heerspink HJ
Adv Chronic Kidney Dis; 2011 Jul; 18(4):290-9. PubMed ID: 21782135
[TBL] [Abstract][Full Text] [Related]
11. [Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)].
Santoro A; Mandreoli M
G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786183
[TBL] [Abstract][Full Text] [Related]
12. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
Werner C; Pöss J; Böhm M
Drugs; 2010 Jul; 70(10):1215-30. PubMed ID: 20568830
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis.
Susantitaphong P; Sewaralthahab K; Balk EM; Eiam-ong S; Madias NE; Jaber BL
Am J Hypertens; 2013 Mar; 26(3):424-41. PubMed ID: 23382494
[TBL] [Abstract][Full Text] [Related]
14. An Overview of Clinically Imperative and Pharmacodynamically Significant Drug Interactions of Renin-Angiotensin-Aldosterone System (RAAS) Blockers.
Mohamed Pakkir Maideen N; Balasubramanian R; Muthusamy S; Nallasamy V
Curr Cardiol Rev; 2022; 18(6):e110522204611. PubMed ID: 35546745
[TBL] [Abstract][Full Text] [Related]
15. Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease.
Komers R; Plotkin H
Am J Physiol Regul Integr Comp Physiol; 2016 May; 310(10):R877-84. PubMed ID: 27009050
[TBL] [Abstract][Full Text] [Related]
16. Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation?
Sarafidis PA; Ruilope LM
Kidney Int; 2014 Mar; 85(3):536-46. PubMed ID: 24048382
[TBL] [Abstract][Full Text] [Related]
17. Renin-angiotensin-aldosterone system inhibition: overview of the therapeutic use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, and direct renin inhibitors.
Mercier K; Smith H; Biederman J
Prim Care; 2014 Dec; 41(4):765-78. PubMed ID: 25439533
[TBL] [Abstract][Full Text] [Related]
18. Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease.
Yamout H; Lazich I; Bakris GL
Adv Chronic Kidney Dis; 2014 May; 21(3):281-6. PubMed ID: 24780456
[TBL] [Abstract][Full Text] [Related]
19. Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria.
Morales E; Gutiérrez E; Caro J; Sevillano A; Rojas-Rivera J; Praga M
Nefrologia; 2015; 35(6):554-61. PubMed ID: 26519114
[TBL] [Abstract][Full Text] [Related]
20. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
